Cardiol Therapeutics files patent to use CBD therapies for patients with coronavirus
Education Industry News
Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) has filed a new patent application to cover the use of cannabidiol in patients with COVID-19, the disease caused by coronavirus.
Cannabidiol, or CBD, could reduce the severity and prevent the progression of COVID-19 symptoms in patients with pre-existing cardiovascular conditions, according to Cardiol.
The Oakville-based company is developing CBD-based therapies for heart disease as well as proprietary nanotechnology to deliver pharmaceutical cannabidiol directly into sites of inflammation in the heart.